These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R; Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398 [TBL] [Abstract][Full Text] [Related]
11. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Farrell RJ; Shah SA; Lodhavia PJ; Alsahli M; Falchuk KR; Michetti P; Peppercorn MA Am J Gastroenterol; 2000 Dec; 95(12):3490-7. PubMed ID: 11151882 [TBL] [Abstract][Full Text] [Related]
12. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Rutgeerts P; Diamond RH; Bala M; Olson A; Lichtenstein GR; Bao W; Patel K; Wolf DC; Safdi M; Colombel JF; Lashner B; Hanauer SB Gastrointest Endosc; 2006 Mar; 63(3):433-42; quiz 464. PubMed ID: 16500392 [TBL] [Abstract][Full Text] [Related]
13. Infliximab in Crohn's disease: first anniversary clinical experience. Cohen RD; Tsang JF; Hanauer SB Am J Gastroenterol; 2000 Dec; 95(12):3469-77. PubMed ID: 11151879 [TBL] [Abstract][Full Text] [Related]
14. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Kinney T; Rawlins M; Kozarek R; France R; Patterson D Am J Gastroenterol; 2003 Mar; 98(3):608-12. PubMed ID: 12650795 [TBL] [Abstract][Full Text] [Related]
15. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease. Gao Q; Hogezand RA; Lamers CB; Verspaget HW Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330 [TBL] [Abstract][Full Text] [Related]
16. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study. Omer B; Krebs S; Omer H; Noor TO Phytomedicine; 2007 Feb; 14(2-3):87-95. PubMed ID: 17240130 [TBL] [Abstract][Full Text] [Related]
17. Infliximab in the treatment of steroid-dependent ulcerative colitis. Armuzzi A; De Pascalis B; Lupascu A; Fedeli P; Leo D; Mentella MC; Vincenti F; Melina D; Gasbarrini G; Pola P; Gasbarrini A Eur Rev Med Pharmacol Sci; 2004; 8(5):231-3. PubMed ID: 15638236 [TBL] [Abstract][Full Text] [Related]
18. Steroid-independent Crohn's disease patients also benefit from combination therapy of infliximab plus azathioprine. van den Brande JM; Peppelenbosch MP; Hommes DW Gastroenterology; 2006 Oct; 131(4):1362-3. PubMed ID: 17030216 [No Abstract] [Full Text] [Related]
19. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Baert F; Moortgat L; Van Assche G; Caenepeel P; Vergauwe P; De Vos M; Stokkers P; Hommes D; Rutgeerts P; Vermeire S; D'Haens G; ; Gastroenterology; 2010 Feb; 138(2):463-8; quiz e10-1. PubMed ID: 19818785 [TBL] [Abstract][Full Text] [Related]
20. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Farrell RJ; Alsahli M; Jeen YT; Falchuk KR; Peppercorn MA; Michetti P Gastroenterology; 2003 Apr; 124(4):917-24. PubMed ID: 12671888 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]